|Title:||Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer – A multi-institutional clinical study in Asia||Authors:||Yang P.-C.
|Issue Date:||2020||Publisher:||W.B. Saunders Ltd||Journal Volume:||46||Journal Issue:||5||Start page/Pages:||811-817||Source:||European Journal of Surgical Oncology||Abstract:||
Introduction: Irreversible electroporation (IRE) is a modality that utilizes high electric voltage to cause cell apoptosis. IRE has been used to treat locally advanced pancreatic cancer (LAPC). However, studies of IRE via surgical approaches for LAPC are limited. This study aims to analyse the outcomes and related prognostic factors of IRE for Asian patients with LAPC. Materials and methods: From 2012 to 2017, this prospective trial for using IRE through surgical approaches for LAPC was conducted in 11 medical centres in Asia. All related and treatment outcomes were analysed from a prospective database. Results: Seventy-four patients were enrolled. Thirty complications occurred in thirteen (17.6%) patients without mortality. The electrode placement direction (anteroposterior vs. craniocaudal, HR = 14.2, p < 0.01) and gastrointestinal invasion (HR = 15.7, p < 0.01) were significant factors for complications. The progression-free survival (PFS) rate in one year, three years, and five years were 69.1%, 48.7%, and 28.8%, and the overall survival (OS) rate in one year, three years, and five years were 97.2%, 53%, and 31.2%. In univariate analysis, the chemotherapy regimen, local tumour recurrence, axial tumour length, tumour volume, and serum carbohydrate antigen 19-9 levels were all significantly associated with PFS and OS. In multivariate analysis, the chemotherapy regimen was the only significant factor associated with PFS and OS. TS-1 (Tegafur, gimeracil, and oteracil) group has superior survival outcome than gemcitabine group. Conclusion: This study showed that combined induction chemotherapy and surgical IRE for LAPC is safe. For well-selected patients, IRE can achieve encouraging survival outcomes. ? 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
|ISSN:||0748-7983||DOI:||10.1016/j.ejso.2019.12.006||SDG/Keyword:||CA 19-9 antigen; gemcitabine; gimeracil plus oteracil potassium plus tegafur; ts 1; antineoplastic agent; deoxycytidine; gemcitabine; oteracil; pyridine derivative; tegafur; tegafur-gimeracil-oteracil; abdominal disease; abdominal infection; abdominal pain; adult; advanced cancer; aged; Article; Asia; Asian; cancer combination chemotherapy; cancer mortality; cancer prognosis; cancer recurrence; cancer survival; clinical outcome; controlled study; factor analysis; false aneurysm; female; flatulence; follow up; gastrointestinal hemorrhage; hepatitis; hospitalization; human; induction chemotherapy; intraabdominal fluid accumulation; irreversible electroporation; laparotomy; major clinical study; male; overall survival; pancreas cancer; pancreas fistula; postoperative complication; priority journal; prognostic assessment; progression free survival; prospective study; protein blood level; tumor volume; adenocarcinoma; cancer staging; clinical trial; drug combination; electroporation; metabolism; middle aged; multicenter study; neoadjuvant therapy; pancreas tumor; pathology; procedures; prognosis; proportional hazards model; tumor recurrence; very elderly; young adult; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Electroporation; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Proportional Hazards Models; Pyridines; Tegafur; Young Adult
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.